1079 related articles for article (PubMed ID: 27099835)
1. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.
Bartalena L; Baldeschi L; Boboridis K; Eckstein A; Kahaly GJ; Marcocci C; Perros P; Salvi M; Wiersinga WM;
Eur Thyroid J; 2016 Mar; 5(1):9-26. PubMed ID: 27099835
[TBL] [Abstract][Full Text] [Related]
2. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
3. Graves' orbitopathy: imperfect treatments for a rare disease.
Bartalena L
Eur Thyroid J; 2013 Dec; 2(4):259-69. PubMed ID: 24783057
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
5. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
6. [Graves' ophthalmopathy].
Eckstein A; Dekowski D; Führer-Sakel D; Berchner-Pfannschmidt U; Esser J
Ophthalmologe; 2016 Apr; 113(4):349-64; quiz 465-6. PubMed ID: 27059986
[TBL] [Abstract][Full Text] [Related]
7. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
Marcocci C; Marinò M
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
[TBL] [Abstract][Full Text] [Related]
8. Commentary: rituximab, adalimumab, etanercept, tocilizumab--are biologics the future for Graves' orbitopathy?
Bartalena L
Ophthalmic Plast Reconstr Surg; 2014; 30(5):420-3. PubMed ID: 25025391
[TBL] [Abstract][Full Text] [Related]
9. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
10. [Management of Graves' orbitopathy: evidence-based recommendations].
Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
[TBL] [Abstract][Full Text] [Related]
11. Extrathyroidal manifestations of Graves' disease: a 2014 update.
Bartalena L; Fatourechi V
J Endocrinol Invest; 2014 Aug; 37(8):691-700. PubMed ID: 24913238
[TBL] [Abstract][Full Text] [Related]
12. A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy.
Negro R; Hegedüs L; Attanasio R; Papini E; Winther KH
Eur Thyroid J; 2019 Jan; 8(1):7-15. PubMed ID: 30800636
[TBL] [Abstract][Full Text] [Related]
13. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
14. [Management of patient with Gaves' orbitopathy].
Di Fiore A; Paone L; Rendina R; D'Armiento E; Coccaro C; Alessandrini S; Marenco M; Ulisse S
Clin Ter; 2012 Nov; 163(6):e463-74. PubMed ID: 23306763
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
16. [Endoscopic decompression of orbit in Graves' orbitopathy].
Poślednik KB; Miśkiewicz P; Jabłońska-Pawlak A; Kantor I; Szczepański MJ
Pol Merkur Lekarski; 2019 May; 46(275):224-228. PubMed ID: 31152536
[TBL] [Abstract][Full Text] [Related]
17. Graves' orbitopathy: Management of difficult cases.
Wiersinga WM
Indian J Endocrinol Metab; 2012 Dec; 16(Suppl 2):S150-2. PubMed ID: 23565365
[TBL] [Abstract][Full Text] [Related]
18. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
[TBL] [Abstract][Full Text] [Related]
19. Current Knowledge on Graves' Orbitopathy.
Gontarz-Nowak K; Szychlińska M; Matuszewski W; Stefanowicz-Rutkowska M; Bandurska-Stankiewicz E
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374706
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]